



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/700,816
				Filing Date	November 4, 2003
				First Named Inventor	Zuoshang Xu
				Art Unit	4632 1635
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	UMY-038

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
SM	A1	2003/0180756 A1	09-25-2003	Shi, Y., <i>et al.</i>	
	A2	2003/0190635 A1	10-09-2003	McSwiggen, J.A.	
	A3	2004/0192629 A1	09-30-2004	Xu, Z., <i>et al.</i>	
	A4	2004/0214198 A1	10-28-2004	Rana, T.M	
	A5	2004/0219671 A1	11-04-2004	McSwiggen, J.A., <i>et al.</i>	
	A6	2004/0241854 A1	12-02-2004	Davidson, B.L., <i>et al.</i>	
	A7	2004/0023390 A1	02-05-2004	Davidson, B.L., <i>et al.</i>	
	A8	2005/0042646 A1	02-24-2005	Davidson, B.L., <i>et al.</i>	
	A9	2005/0130184 A1	06-16-2005	Xu, Z., <i>et al.</i>	
	A10	2005/0130919 A1	06-16-2005	Xu, Z., <i>et al.</i>	
SM	A11	2005/0137155 A1	06-23-2005	McSwiggen, J.A., <i>et al.</i>	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
SM	B1	WO 03/070895 A2	08-28-2003	Ribozyme Pharmaceuticals, Inc.	
	B2	WO 03/080807 A2	10-02-2003	President and Fellows of Harvard College	
	B3	WO 2004/013280 A2	02-12-2004	University of Iowa Research Foundation	
	B4	WO 2004/01335 A1	02-12-2004	University of Iowa Research Foundation	
	B5	WO 2004/013310 A2	02-12-2004	Intradigm Corporation	
	B6	WO 2004/042027 A2	05-21-2004	University of Massachusetts	
	B7	WO 2004/046324 A2	06-03-2004	University of Massachusetts	
	B8	WO 2004/058940 A2	07-15-2004	University of Iowa Research Foundation	
	B9	WO 2005/003350 A2	01-13-2005	Ribozyme Pharmaceuticals, Inc.	
	B10	WO 2005/007875 A2	01-27-2005	University of Massachusetts	
	B11	WO 2005/007877 A2	01-27-2005	University of Massachusetts	
	B12	WO 2005/023991 A2	03-17-2005	The General Hospital Corporation	
SM	B13	WO 2005/027980 A1	03-31-2005	University of Massachusetts	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/700,816
				Filing Date	November 4, 2003
				First Named Inventor	Zuoshang Xu
				Art Unit	4092 1635
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	UMY-038

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
SM	B14	WO 2005/045034 A2	07-19-2005	Ribozyme Pharmaceuticals, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SM	C1	Harper, S.Q., <i>et al.</i> "RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model." <i>Proc Natl Acad Sci USA</i> . 2005 Apr 19; 102(16): 5820-25	
	C2	Maxwell, M.M., <i>et al.</i> RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells." <i>Proc Natl Acad Sci USA</i> 2004 Mar. 2; 101(9): 3178-83	
	C3	Miller, V.M., <i>et al.</i> "Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles." <i>Nucleic Acids Research Oxford University Press</i> 2004; 32(2): 661-668	
	C4	Ralph, S.G., <i>et al.</i> "Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model" <i>Nature Medicine</i> . 2005 Apr; 11(4)	
	C5	Raoul, C. <i>et al.</i> "Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS." <i>Nature Medicine</i> . 2005 Apr; 11(4)	
	C6	Rival, T. <i>et al.</i> "Decreasing glutamate buffering capacity triggers oxidative stress and neuropil degeneration in the <i>drosophila</i> brain." <i>Current Biology</i> . 2004 Apr. 6; 14:599-605.	
	C7	Sui G., <i>et al.</i> "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells." <i>Proc Natl Acad Sci USA</i> 2002 Apr 16;99(8): 5515-5520	
	C8	Veldink, J.H., <i>et al.</i> "The future of motor neuron disease." <i>J Neurol</i> . 2004; 251:491-500.	
	C9	Xia, X.G., <i>et al.</i> "An enhanced U6 promoter for synthesis of short hairpin RNA." <i>Nucleic Acids Res</i> . 2003 Sep 1; 31(17):e100 (5 pages).	
	C10	Xia, X.G., <i>et al.</i> "An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase." <i>J Neurochem</i> . 2005 Jan; 92(2):362-7	
	C11	Xie, J., <i>et al.</i> "RNAi knockdown of Par-4 inhibits neurosynaptic degeneration in ALS-linked mice." <i>J Neurochem</i> . 2005 Jan; 92(1):59-71.	
SM	C12	Xie, Z., <i>et al.</i> "Effects of RNA interference-mediated silencing of γ -secretase complex components on cell sensitivity to caspase-3 activation." <i>The Journal of Biological Chemistry</i> . 2004 Aug 13; 279(33):34130-7.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/700,816
				Filing Date	November 4, 2003
				First Named Inventor	Zuoshang Xu
				Art Unit	4602 1635
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	UMY-038

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SM	C13	Miller, V.M., <i>et al.</i> "Allele-specific silencing of dominant disease genes." <i>Proc Natl Acad Sci USA</i> . 2003 Jun 10; 100(12): 7195-7200	
SM	C14	Ding, H. <i>et al.</i> , "Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis" <i>Aging Cell</i> 2003;2:209-217	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Sean McGarry/	Date Considered	02/12/2007
-----------------------	----------------	--------------------	------------